Main Products/ Services/ Pipelines & Platforms
We have discovered and was awarded US patents a remarkable molecule BAE with the following medicinal applications: • macular edema (ME). • wet age-related macular degeneration (wet AMD). • non-proliferation diabetic retinopathy (NPDR). Orally, in the 28-day test of NPDR Indian rhesus monkeys, it was confirmed that it was effective in improving macular leakage, and abnormalities were found 56 days after drug withdrawal. At present, the pharmacological effects are known, and many studies have been carried out. BAE effectively treats microvascular leakage in NPDR, avoiding blurred vision or even blindness at the PDR stage.
Business Interests
We are looking for business partners, hoping to have more funds to enter preclinical animal tests and IND; or, Out-Licensing. According to the authoritative Grand View Research report: In the NPDR stage, the global market will exceed US 10 billion annually.
Contact Info
CHAO-MIN HSU
President
+886-2-2378-0588
jimmy@zih-yuan-tang.com